Recombinant Human CD19 Fc Chimera Biotinylated Protein, CF New

Catalog #: BT9269 Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
BT9269-050

Save 15% on Select RUO Reagents. See Details.

Biotinylated Recombinant Human CD19 Fc Chimera Protein Binding Activity.

2 Images

Product Details

Supplemental Products

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human CD19 Fc Chimera Biotinylated Protein, CF Summary

R&D Systems CHO-derived Recombinant Human CD19 Fc Chimera Biotinylated Protein (BT9269)
Quality control testing to verify active proteins with lot specific assays by in-house scientists
All R&D Systems proteins are covered with a 100% guarantee

Product Specifications

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

Activity

Measured by its binding ability in a functional ELISA. Biotinylated Recombinant Human CD19 Fc Chimera binds to Human CD19 Antibody (Catalog # MAB4867) with an ED₅₀ of 25.0-250 ng/mL.

Source

Chinese Hamster Ovary cell line, CHO-derived human CD19 protein

Human CD19 (Glu21-Lys291) Accession # P15391	IEGRMD	Human IgG₁ (Pro100-Lys330)
N-terminus		C-terminus

N-terminal Sequence
Analysis

Glu21

Structure / Form

Disulfide linked homodimer, Biotinylated via amines

Predicted Molecular Mass

57 kDa

SDS-PAGE

75-90 kDa, under reducing conditions

Product Datasheets

BT9269

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

BT9269

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution	Reconstitute at 500 μg/mL in water.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

Binding Activity

View Larger

Measured by its binding ability in a functional ELISA. Biotinylated Recombinant Human CD19 Fc Chimera (Catalog # BT9269) binds to Human CD19 Antibody (MAB4867) with an ED₅₀ of 25.0-250 ng/mL.

SDS-PAGE

View Larger

2 μg/lane of Biotinylated Recombinant Human CD19 Fc Chimera Protein (Catalog # BT9269) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 75-90 kDa and 150-180 kDa, respectively.

Reconstitution Calculator

Background: CD19

CD19 protein is a 95 kDa transmembrane glycoprotein that plays a central role in B cell activation and humoral immune responses (1, 2). CD19 is expressed throughout B cell development from pre-B cells through mature B cells, and it is commonly used as a B cell lineage marker (1). It is required for the responsiveness of mature B cell to antigen stimulation, germinal center development, and antibody affinity maturation (4, 5). The CD19 protein associates with the B cell antigen receptor (BCR), CD81, CD38, CD21, CD22, and IFITM1/CD225/Leu13, (6-9). These associations enable CD19 to amplify B cell signaling (7, 9-12) and reduce the threshold for antigen stimulation through the BCR (13). CD19 polymorphisms and up-regulation can lead to the development of autoimmunity by promoting autoantibody production (2). CD19 has emerged as promising therapeutic target for hematologic cancers and solid tumors. Immunotherapy using a chimeric antigen receptor (CAR) targeting CD19 has proven effective in many different cancers. The first CD19 CAR T cell therapies have been granted FDA approval for the treatment of B cell malignancies with several more in clinical trials. Mature human CD19 protein consists of a 272 amino acid (aa) extracellular domain (ECD) with two Ig-like domains, a 22 aa transmembrane segment, and a 243 aa cytoplasmic domain (3). Within the ECD, human CD19 shares 57% amino acid sequence identity with mouse and rat CD19.

References

Wang, K. et al. (2012) Exp. Hematol. Oncol. 1:36.
Tedder, T.F. et al. (1997) Immunity 6:107.
Tedder, T.F. and C.M. Isaacs (1989) J. Immunol. 143:712.
Rickert, R.C. et al. (1995) Nature 376:352.
Engel, P. et al. (1995) Immunity 3:39.
Vences-Catalan, F. et al. (2012) J. Immunol. 137:48.
Deaglio, S. et al. (2007) Blood 109:5390.
Bradbury, L. et al. (1992) J. Immunol. 149:2841.
Krop, I. et al. (1996) J. Immunol. 157:48.
O'Rourke, L.M. et al. (1998) Immunity 8:635.
Buhl, A.M. et al. (1997) J. Exp. Med. 186:1897.
Sato, S. et al. (1995) Proc. Natl. Acad. Sci. USA 92:11558.
Carter, R.H. and D.T. Fearon (1992) Science 256:105.

Entrez Gene IDs

930 (Human); 12478 (Mouse); 365367 (Rat); 397669 (Porcine); 607898 (Canine); 102145514 (Cynomolgus Monkey); 100147468 (Equine)

Alternate Names

B4; B-lymphocyte antigen CD19; B-lymphocyte surface antigen B4; CD19 antigen; CD19 molecule; CD19; CVID3; Differentiation antigen CD19; Leu-12; MGC12802; T-cell surface antigen Leu-12